RNS Number : 1069L
Neuropharm Group PLC
30 April 2010
|
For immediate release
|
30 April 2010
|
Neuropharm Group plc
("Neuropharm" or the "Company")
Issue of Equity
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, announces the issue of 1,200,000 new ordinary shares of 10p each in the Company ("Ordinary Shares") following the exercise of options granted to Professor Eric Hollander and Professor Mark Smith in March 2006. As a result, the Company's issued share capital now consists of 32,736,697 ordinary shares of 10p each, with one voting right per share. The Company holds no ordinary shares in Treasury, therefore, the total number of voting rights in the Company is 32,736,697.
For further information please contact:
Neuropharm
|
+ 44 (0) 1372 371 171
|
|
Robert Mansfield, Chief Executive Officer
Graham Yeatman, Chief Financial Officer
|
|
|
|
|
Piper Jaffray Ltd.
|
+ 44 (0) 20 3142 8700
|
|
Neil Mackison, Rupert Winckler
|
|
|
|
|
Buchanan Communications
|
+ 44 (0) 20 7466 5000
|
|
Mark Court, Catherine Breen
|
|
Notes to Editors:
About Neuropharm
Neuropharm is a speciality pharmaceutical company focused on the development of medicines for the treatment and management of neurodevelopmental disorders. Please visit www.neuropharm.co.uk for further information.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEZBLBXBZFXBBZ